Cargando…
A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI)
PURPOSE: This study aimed to establish the maximum tolerated dose of concurrent chemoradiotherapy (cCRT) with conventional administration of the docetaxel (D) plus cisplatin (P) (conv-DP) regimen. METHODS: Patients (aged ≤70 years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362714/ https://www.ncbi.nlm.nih.gov/pubmed/22565592 http://dx.doi.org/10.1007/s00280-012-1871-5 |
_version_ | 1782234244973592576 |
---|---|
author | Hida, Naoya Okamoto, Hiroaki Misumi, Yuuki Sato, Akira Ishii, Mari Kashizaki, Fumihiro Shimokawa, Tsuneo Shimizu, Teppei Watanabe, Koshiro |
author_facet | Hida, Naoya Okamoto, Hiroaki Misumi, Yuuki Sato, Akira Ishii, Mari Kashizaki, Fumihiro Shimokawa, Tsuneo Shimizu, Teppei Watanabe, Koshiro |
author_sort | Hida, Naoya |
collection | PubMed |
description | PURPOSE: This study aimed to establish the maximum tolerated dose of concurrent chemoradiotherapy (cCRT) with conventional administration of the docetaxel (D) plus cisplatin (P) (conv-DP) regimen. METHODS: Patients (aged ≤70 years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) and having performance status 0 or 1 and adequate organ function were eligible. They received radiotherapy (60 Gy in 30 fractions) once daily starting on day 2. Concurrent P (day 1; 60 mg/m(2) at Levels 1–3, 80 mg/m(2) at Level 4) and D (day 1; 30 mg/m(2) at Level 1, 40 mg/m(2) at Level 2, 50 mg/m(2) at Levels 3–4) were administered every 4 weeks for 2–4 courses. RESULTS: Eighteen patients were enrolled (stage IIIA/IIIB, 5/13 patients). Three cases of dose-limiting toxicity were observed in this study, although another 3 cases were added at Levels 2 and 3. Radiotherapy was completed in 15 patients. Seventeen patients received more than 2 courses of chemotherapy. Neither Grade 3/4 esophagitis nor severe hematological events were observed at Levels 1–4. However, dose escalation to Level 5 (P [80 mg/m(2)], D [60 mg/m(2)]) was stopped because the Level 5 dose was the recommended dose (RD) of chemotherapy alone for stage IIIB/IV NSCLC in Japan. Therefore, the RD was determined as D50/P80 mg/m(2) in this cCRT. The objective response rate was 89 %, and the median survival time was 23.6 months. CONCLUSIONS: cCRT with non-split DP was a tolerable and effective regimen, and RD was 50/80 mg/m(2) every 4 weeks. |
format | Online Article Text |
id | pubmed-3362714 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Springer-Verlag |
record_format | MEDLINE/PubMed |
spelling | pubmed-33627142012-06-13 A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) Hida, Naoya Okamoto, Hiroaki Misumi, Yuuki Sato, Akira Ishii, Mari Kashizaki, Fumihiro Shimokawa, Tsuneo Shimizu, Teppei Watanabe, Koshiro Cancer Chemother Pharmacol Original Article PURPOSE: This study aimed to establish the maximum tolerated dose of concurrent chemoradiotherapy (cCRT) with conventional administration of the docetaxel (D) plus cisplatin (P) (conv-DP) regimen. METHODS: Patients (aged ≤70 years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) and having performance status 0 or 1 and adequate organ function were eligible. They received radiotherapy (60 Gy in 30 fractions) once daily starting on day 2. Concurrent P (day 1; 60 mg/m(2) at Levels 1–3, 80 mg/m(2) at Level 4) and D (day 1; 30 mg/m(2) at Level 1, 40 mg/m(2) at Level 2, 50 mg/m(2) at Levels 3–4) were administered every 4 weeks for 2–4 courses. RESULTS: Eighteen patients were enrolled (stage IIIA/IIIB, 5/13 patients). Three cases of dose-limiting toxicity were observed in this study, although another 3 cases were added at Levels 2 and 3. Radiotherapy was completed in 15 patients. Seventeen patients received more than 2 courses of chemotherapy. Neither Grade 3/4 esophagitis nor severe hematological events were observed at Levels 1–4. However, dose escalation to Level 5 (P [80 mg/m(2)], D [60 mg/m(2)]) was stopped because the Level 5 dose was the recommended dose (RD) of chemotherapy alone for stage IIIB/IV NSCLC in Japan. Therefore, the RD was determined as D50/P80 mg/m(2) in this cCRT. The objective response rate was 89 %, and the median survival time was 23.6 months. CONCLUSIONS: cCRT with non-split DP was a tolerable and effective regimen, and RD was 50/80 mg/m(2) every 4 weeks. Springer-Verlag 2012-05-08 2012 /pmc/articles/PMC3362714/ /pubmed/22565592 http://dx.doi.org/10.1007/s00280-012-1871-5 Text en © The Author(s) 2012 https://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited. |
spellingShingle | Original Article Hida, Naoya Okamoto, Hiroaki Misumi, Yuuki Sato, Akira Ishii, Mari Kashizaki, Fumihiro Shimokawa, Tsuneo Shimizu, Teppei Watanabe, Koshiro A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title_full | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title_fullStr | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title_full_unstemmed | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title_short | A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer (JCOG9901DI) |
title_sort | phase i trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage iii non-small-cell lung cancer (jcog9901di) |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3362714/ https://www.ncbi.nlm.nih.gov/pubmed/22565592 http://dx.doi.org/10.1007/s00280-012-1871-5 |
work_keys_str_mv | AT hidanaoya aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT okamotohiroaki aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT misumiyuuki aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT satoakira aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT ishiimari aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT kashizakifumihiro aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT shimokawatsuneo aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT shimizuteppei aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT watanabekoshiro aphaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT hidanaoya phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT okamotohiroaki phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT misumiyuuki phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT satoakira phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT ishiimari phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT kashizakifumihiro phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT shimokawatsuneo phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT shimizuteppei phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di AT watanabekoshiro phaseitrialofconcurrentchemoradiotherapywithnonsplitadministrationofdocetaxelandcisplatinfordrystageiiinonsmallcelllungcancerjcog9901di |